Cargando…

COVID-19 vaccine hesitancy in eight European countries: Prevalence, determinants, and heterogeneity

We examine heterogeneity in COVID-19 vaccine hesitancy across eight European countries. We reveal striking differences across countries, ranging from 6.4% of adults in Spain to 61.8% in Bulgaria reporting being hesitant. We experimentally assess the effectiveness of different messages designed to re...

Descripción completa

Detalles Bibliográficos
Autores principales: Steinert, Janina I., Sternberg, Henrike, Prince, Hannah, Fasolo, Barbara, Galizzi, Matteo M., Büthe, Tim, Veltri, Giuseppe A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045608/
https://www.ncbi.nlm.nih.gov/pubmed/35476432
http://dx.doi.org/10.1126/sciadv.abm9825
_version_ 1784695351494574080
author Steinert, Janina I.
Sternberg, Henrike
Prince, Hannah
Fasolo, Barbara
Galizzi, Matteo M.
Büthe, Tim
Veltri, Giuseppe A.
author_facet Steinert, Janina I.
Sternberg, Henrike
Prince, Hannah
Fasolo, Barbara
Galizzi, Matteo M.
Büthe, Tim
Veltri, Giuseppe A.
author_sort Steinert, Janina I.
collection PubMed
description We examine heterogeneity in COVID-19 vaccine hesitancy across eight European countries. We reveal striking differences across countries, ranging from 6.4% of adults in Spain to 61.8% in Bulgaria reporting being hesitant. We experimentally assess the effectiveness of different messages designed to reduce COVID-19 vaccine hesitancy. Receiving messages emphasizing either the medical benefits or the hedonistic benefits of vaccination significantly increases COVID-19 vaccination willingness in Germany, whereas highlighting privileges contingent on holding a vaccination certificate increases vaccination willingness in both Germany and the United Kingdom. No message has significant positive effects in any other country. Machine learning–based heterogeneity analyses reveal that treatment effects are smaller or even negative in settings marked by high conspiracy beliefs and low health literacy. In contrast, trust in government increases treatment effects in some groups. The heterogeneity in vaccine hesitancy and responses to different messages suggests that health authorities should avoid one-size-fits-all vaccination campaigns.
format Online
Article
Text
id pubmed-9045608
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-90456082022-05-04 COVID-19 vaccine hesitancy in eight European countries: Prevalence, determinants, and heterogeneity Steinert, Janina I. Sternberg, Henrike Prince, Hannah Fasolo, Barbara Galizzi, Matteo M. Büthe, Tim Veltri, Giuseppe A. Sci Adv Social and Interdisciplinary Sciences We examine heterogeneity in COVID-19 vaccine hesitancy across eight European countries. We reveal striking differences across countries, ranging from 6.4% of adults in Spain to 61.8% in Bulgaria reporting being hesitant. We experimentally assess the effectiveness of different messages designed to reduce COVID-19 vaccine hesitancy. Receiving messages emphasizing either the medical benefits or the hedonistic benefits of vaccination significantly increases COVID-19 vaccination willingness in Germany, whereas highlighting privileges contingent on holding a vaccination certificate increases vaccination willingness in both Germany and the United Kingdom. No message has significant positive effects in any other country. Machine learning–based heterogeneity analyses reveal that treatment effects are smaller or even negative in settings marked by high conspiracy beliefs and low health literacy. In contrast, trust in government increases treatment effects in some groups. The heterogeneity in vaccine hesitancy and responses to different messages suggests that health authorities should avoid one-size-fits-all vaccination campaigns. American Association for the Advancement of Science 2022-04-27 /pmc/articles/PMC9045608/ /pubmed/35476432 http://dx.doi.org/10.1126/sciadv.abm9825 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC). https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial license (https://creativecommons.org/licenses/by-nc/4.0/) , which permits use, distribution, and reproduction in any medium, so long as the resultant use is not for commercial advantage and provided the original work is properly cited.
spellingShingle Social and Interdisciplinary Sciences
Steinert, Janina I.
Sternberg, Henrike
Prince, Hannah
Fasolo, Barbara
Galizzi, Matteo M.
Büthe, Tim
Veltri, Giuseppe A.
COVID-19 vaccine hesitancy in eight European countries: Prevalence, determinants, and heterogeneity
title COVID-19 vaccine hesitancy in eight European countries: Prevalence, determinants, and heterogeneity
title_full COVID-19 vaccine hesitancy in eight European countries: Prevalence, determinants, and heterogeneity
title_fullStr COVID-19 vaccine hesitancy in eight European countries: Prevalence, determinants, and heterogeneity
title_full_unstemmed COVID-19 vaccine hesitancy in eight European countries: Prevalence, determinants, and heterogeneity
title_short COVID-19 vaccine hesitancy in eight European countries: Prevalence, determinants, and heterogeneity
title_sort covid-19 vaccine hesitancy in eight european countries: prevalence, determinants, and heterogeneity
topic Social and Interdisciplinary Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045608/
https://www.ncbi.nlm.nih.gov/pubmed/35476432
http://dx.doi.org/10.1126/sciadv.abm9825
work_keys_str_mv AT steinertjaninai covid19vaccinehesitancyineighteuropeancountriesprevalencedeterminantsandheterogeneity
AT sternberghenrike covid19vaccinehesitancyineighteuropeancountriesprevalencedeterminantsandheterogeneity
AT princehannah covid19vaccinehesitancyineighteuropeancountriesprevalencedeterminantsandheterogeneity
AT fasolobarbara covid19vaccinehesitancyineighteuropeancountriesprevalencedeterminantsandheterogeneity
AT galizzimatteom covid19vaccinehesitancyineighteuropeancountriesprevalencedeterminantsandheterogeneity
AT buthetim covid19vaccinehesitancyineighteuropeancountriesprevalencedeterminantsandheterogeneity
AT veltrigiuseppea covid19vaccinehesitancyineighteuropeancountriesprevalencedeterminantsandheterogeneity